Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

NCT03199040 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

18

Enrollment

OTHER

Sponsor class

Stopped Drugs/equipment unavailable and insufficient funding

Conditions

Triple Negative Breast Cancer
Triple Negative Breast Neoplasms
TNBC - Triple-Negative Breast Cancer
Triple-negative Breast Carcinoma

Interventions

DRUG: Durvalumab
BIOLOGICAL: Neoantigen DNA vaccine
DEVICE: TDS-IM system (Inchor Medical Systems)
PROCEDURE: Peripheral blood draw

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]
[object Object]